Press Release FeedGet the RSS feed
Menu

GlobeNewswire

圖靈獎得主約瑟夫·希發基斯到訪曹操出行AI創新中心，見證Robotaxi網站可信決策與多智慧體協同研究專案啟動

GlobeNewswire

中國上海, Oct. 23, 2026 -- 10月21日，圖靈獎得主、曹操出行AI創新中心首席科學顧問約瑟夫·希發基斯（Joseph Sifakis）教授到訪曹操出行AI創新中心，與曹操出行技術團隊進行深度業務交流。當天，曹操出行啟動Robotaxi網站可信決策與多智慧體協同研究專案，希發基斯教授見證專案啟動，並結合自身研究經驗提出了寶貴建議。

希發基斯教授是模型檢測領域的開創者之一，因推動模型檢測理論及應用發展獲得2007年圖靈獎，他長期致力於複雜智慧系統及可信自主系統研究，研究方向與Robotaxi規模化運營面臨的安全可信問題密切相關。

今年6月，希發基斯教授正式受邀出任曹操出行AI創新中心首席科學顧問，為公司AI轉型與自動駕駛技術發展提供學術支援。在今年世界人工智慧大會（WAIC 2026）期間，希發基斯教授提出，可信Robotaxi應遵循構造即安全、系統協同和運行保障三項原則，認為曹操出行所構建的RoboX體系，與可信自主系統的系統性工程理念高度契合。

在Robotaxi出行服務中，上下車是乘客體驗的關鍵環節。本次啟動的Robotaxi網站可信決策與多智慧體協同研究專案將安全可信問題聚焦到乘客上下客這一高頻出行場景，探索將可信自主系統理論轉化為可檢驗的工程方法。

基於曹操出行11年出行服務的真實運營資料與經驗，專案圍繞停靠位置的使用條件、乘客上下車路徑、車輛停靠行為及系統協作，探索通過模擬測試與實車測試交叉驗證方法，積累可複用的場景證據，為Robotaxi業務跨城市可信遷移與全球部署提供安全驗證依據。

聯絡人：Jing Liu
電郵：[email protected]

此公告隨附的照片可在以下網址查看：https://www.globenewswire.com/NewsRoom/AttachmentNg/66d7d57d-af7c-4812-91ed-15420008c24e/zh-Hant

  1. eSUN Introduces eBOX Plus: An Intelligent Filament Dryer with 80°C Heating and Four-Spool CapacityeSUN has introduced eBOX Plus, a new-generation filament dryer designed to improve moisture management and printing reliability for FDM 3D printing. With capacity for up to four spools of the same filament type, a maximum drying temperature of 80°C, and intelligent active dehumidification, eBOX Plus combines high-capacity drying with practical features for everyday printing workflows.
  2. Form 8.5 (EPT/RI) - Kore Potash PlcFORM 8.5 (EPT/RI)
  3. Form 8.5 (EPT/RI) - CAB Payments Holdings PlcFORM 8.5 (EPT/RI)
  4. Government & policyRESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDSOctober 23, 2026 04:05 ET | Source: Sveriges Riksbank Auction date 2026-10-23 Loan 3114 Coupon 0.125 % ISIN-code SE0013748258 Maturity 2030-06-01 Tendered volume, SEK mln 200 +/- 200 Total bid volume, SEK mln 1,100 Volume sold, SEK mln 200 Number of bids 11 Number of accepted bids 1 Average yield 0.789 % Lowest yield 0.789 % Highest accepted yield 0.789 % % accepted at highest yield 100.00 Auction date 2026-10-23 Loa
  5. FinancePhathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAPhathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom’s New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.
  6. Biotech & pharmaPhase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerSTAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO